OptraSCAN Bags $30 Mn in Series B Funding to Advance Digital Pathology Solutions

The funding will be utilized to expand OptraSCAN’s AI-driven digital pathology solutions and strengthen its global footprint, focusing on making diagnostic technology more accessible and affordable.

OptraSCAN, a digital pathology solutions provider, has raised $30 million in a Series B funding round led by Molbio Diagnostics.

The funding will be utilized to expand OptraSCAN’s AI-driven digital pathology solutions and strengthen its global footprint, focusing on making diagnostic technology more accessible and affordable.

The investment will enhance OptraSCAN’s cloud-enabled whole-slide scanning systems and AI algorithm suites for accurate and seamless diagnostics.

The funding will also support research and development, sales, and marketing efforts to promote healthcare equity through advanced diagnostics.

“OptraSCAN is thrilled to have Molbio Diagnostics leading this funding round. This investment enables us to expand our digital pathology solutions to more markets, facilitating timely and precise diagnoses globally. Together, we aim to bridge healthcare gaps with affordable, high-quality diagnostic technology,” said Abhi Gholap, Founder and CEO of OptraSCAN. “

Molbio Diagnostics, recognized for its expertise in molecular diagnostics, shares OptraSCAN’s mission to democratize access to healthcare technology.

Commenting on the partnership, Mr Natrajan, Founder and CEO of Molbio Diagnostics, said, “We are excited to lead this funding round, supporting OptraSCAN’s efforts to empower healthcare providers in underserved regions with advanced diagnostic tools.”

OptraSCAN has developed comprehensive digital pathology solutions, including slide scanning, AI-driven analysis, cloud storage, and consultation platforms.

Its flexible pricing models and scalable solutions aim to make digital pathology accessible to laboratories of all sizes.

With six patents and plans for further innovation, the company is set to enhance AI algorithms for pathology and develop tools to assist pathologists in diagnosing diseases more efficiently. The funding positions OptraSCAN to expand its presence in both established and emerging markets.

About OptraSCAN

OptraSCAN is a digital pathology solutions company offering slide scanning, AI-based image analysis, and cloud consultation platforms. Its technology is designed to improve diagnostic accuracy and accessibility, with a focus on affordability and advancing healthcare equity.

OptraSCAN products are CE-IVDR cleared and currently available for research use in the United States.